Danaher announces diagnostic development and commercialization partnership to scale precision medicine

Danaher has entered a partnership with astrazeneca to scale precision medicine, including developing the next generation of ai-powered diagnostics this partnership aims to create a framework for rapid diagnostics research, development and commercialization danaher, through its centers for enabling precision medicine, will provide support in all aspects of the development cycle across diagnostic modalities washington , may 29, 2025 /prnewswire/ -- danaher corporation (nyse: dhr) ("danaher"), a global science and technology innovator, announced today the launch of a partnership with astrazeneca (lse/sto/nasdaq: azn) to develop and commercialize novel diagnostic tools and tests intended to help clinicians better determine which patients would most benefit from precision medicine treatments. "precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit," said julie sawyer montgomery, danaher executive vice president.
DHR Ratings Summary
DHR Quant Ranking